16-30 of 344
- NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Novel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
CME/CENovel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
Alexandria May, PharmD, BCPS
Helena A. Yu, MD
Vicki Sherry, DNP, ANP-BC, AOCNP
Tiffany Traina, MD
Javier Cortes, MD, PhD
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD
Javier Cortes, MD, PhD
- advertisement
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
Tiffany Traina, MD
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD
Javier Cortes, MD, PhD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CEPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
- CME/CE In-Person & Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 11, 2026
Houston, Texas Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME/CECracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
- advertisement
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CEThe Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
